Scope
EAU’s 2026 urolithiasis guideline links emergency drainage, selective observation or intervention, stone analysis and recurrence prevention. This focused summary covers common renal and ureteric decisions, selected pregnancy and childhood considerations, and adult bladder stones. Management depends on infection, obstruction, renal function, stone location and composition; prevention should address measured abnormalities rather than a uniform drug regimen.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Assess the stone and recognise emergencies
- For suspected acute ureteric stones, use ultrasound initially and noncontrast CT to confirm the diagnosis. Immediate imaging is strongly indicated with fever, a solitary kidney or diagnostic uncertainty; imaging must not delay analgesia or emergency treatment. [1]
- Assess urine and blood, including renal function and infection markers. Analyse stones from first-time formers using infrared spectroscopy or X-ray diffraction. Repeat analysis for recurrence despite preventive drugs, early recurrence after complete clearance or late recurrence after a long stone-free interval. [1]
- Sepsis with an obstructing stone is an emergency: urgently drain with a ureteral stent or nephrostomy, obtain urine and blood cultures and start antibiotics immediately. Reassess antibiotics using susceptibility results and postpone definitive stone treatment until sepsis resolves. [1]
- For renal colic, strongly recommend an NSAID first, taking cardiovascular, renal and other adverse-effect risks into account. Opioids or ketamine are weak second-choice options in the acute setting. Analgesia-refractory pain requires decompression or ureteroscopic removal. [1]
Choose observation or intervention deliberately
- Observe newly diagnosed small ureteric stones with periodic review when active removal is unnecessary. For suitable informed patients, the updated section strongly offers off-label alpha-blockers for distal stones 5–10 mm. Stop expulsive treatment if infection, refractory pain or deteriorating renal function develops. [1]
- Remove ureteric stones when passage is unlikely, pain persists despite adequate analgesia, obstruction persists or renal insufficiency is present, including bilateral obstruction or a single kidney. Do not continue observation solely because a stone is small when complications develop. [1]
- Explain that ureteroscopy has a better chance of clearance in one procedure but more complications than shock-wave lithotripsy. Select by size, location, composition, anatomy and patient factors. EAU strongly prefers ureteroscopy for ureteric or renal stones in morbid obesity. [1]
- For renal stones needing treatment, strongly use PCNL first for stones >2 cm. Flexible ureteroscopy or shock-wave treatment are alternatives when PCNL is unsuitable, with possible staged procedures. For lower-pole stones >1 cm, favour PCNL or retrograde intrarenal surgery because shock-wave clearance is limited. [1]
- Before stone removal, obtain urine culture or microscopy and treat infection. Give perioperative antibiotic prophylaxis for endourological treatment. For shock-wave lithotripsy with sterile urine, do not prescribe prophylaxis; reserve it for suspected/confirmed infected stones or bacteriuria. [1]
- Plan antithrombotic interruption or bridging with the prescribing physician. If removal is essential and antithrombotics cannot be stopped, flexible retrograde ureteroscopy is the preferred intervention. Active surveillance is a weak option for asymptomatic calyceal stones when thrombotic risk is high. [1]
- After uncomplicated ureteroscopy with complete clearance, do not routinely insert a stent. Stent patients with higher complication risk, such as trauma, residual fragments, bleeding, perforation, infection or pregnancy. Extract stones only under direct endoscopic vision. [1]
- Uric acid stones may dissolve with supervised urinary alkalinisation; sodium and ammonium urate stones do not share this dissolution rule. Teach urine-pH self-monitoring and review response. Obstructing uric acid stones require drainage alongside chemolysis; allopurinol prevention is for hyperuricosuric urate stone formers. [1]
Adapt the pathway to pregnancy and childhood
- In pregnancy, use ultrasound first, MRI second and low-dose CT only as a last-line option. Manage uncomplicated stones conservatively; persistent or complicated obstruction may require drainage. Shock-wave lithotripsy is contraindicated in pregnancy. [1]
- In children, use ultrasound first; consider KUB radiography or low-dose noncontrast CT when ultrasound cannot supply the required information. Collect stone material and perform metabolic evaluation in every child, with recurrence prevention matched to stone type. [1]
Prevent recurrence using the stone and metabolic profile
- Provide basic metabolic evaluation and reliable stone analysis for all stone formers, then classify recurrence risk. High-risk patients need specific evaluation guided by stone type, including two consecutive 24-hour urine collections. [1]
- After an acute episode, perform specific metabolic testing no earlier than 20 days and preferably around three months, once stable, infection-free and on usual intake. Recheck 24-hour urine eight to twelve weeks after starting preventive medication; annual testing may suffice once values normalise. [1]
- For adult recurrence prevention, favour water and sufficient fluid for urine output >2.5 L/day. Maintain dietary calcium around 1–1.2 g/day rather than routinely restricting it; limit salt to 4–5 g NaCl/day and excessive animal protein. Encourage balanced food and physical activity. [1]
- For calcium oxalate stone formers with measured hypercalciuria, EAU strongly recommends thiazide, alkaline citrate or both; for hypocitraturia use alkaline citrate or bicarbonate. Hyperuricosuria supports allopurinol. Review hydrochlorothiazide skin-cancer risk and arrange regular skin checks; these treatments are not for every calcium stone. [1]
- In enteric hyperoxaluria, strongly advise calcium supplements with meals to bind intestinal oxalate. A low-fat, low-oxalate diet and alkaline citrate are weak recommendations; maintain fluid intake sufficient to balance diarrhoeal losses. [1]
- Refer primary hyperoxaluria to a specialist interdisciplinary centre. For type 1, EAU strongly recommends pyridoxine and recommends lumasiran when pyridoxine does not work. This is a disease-specific pathway requiring expert dosing and monitoring. [1]
- For struvite/infection stones, strongly remove stone material as completely as possible and prescribe antibiotics for persistent bacteriuria. After mixed struvite stones, consider metabolic assessment once stones are removed and infection controlled; postoperative antibiotic duration is not established. [1]
- For adult cystine stone prevention, increase fluid intake to produce >3 L urine daily and use supervised alkalinisation. Add tiopronin when other measures are insufficient; monitor urine protein at baseline and follow-up alongside blood monitoring as part of treatment monitoring. [1]
Check clearance and address bladder stones
- Confirm stone passage and recovery of baseline renal function. After intervention, residual-fragment assessment around four weeks avoids overtreatment of transient dust. EAU weakly recommends treating fragments >4 mm. Use ultrasound/KUB for routine follow-up when appropriate; reserve CT for symptoms or operative planning. [1]
- For suspected bladder stones, use ultrasound first and investigate persistent adult symptoms despite negative ultrasound with cystoscopy, CT or KUB. Identify underlying obstruction, residual urine, infection and metabolic risks. In adults, strongly offer transurethral cystolithotripsy where feasible, or percutaneous treatment when unsuitable. [1]
Limitations and use
- This is a selected pathway summary, not a complete procedure manual, paediatric prescription guide or rare inherited-stone protocol. Transplant kidneys, urinary diversions, neurogenic bladder, renal tubular acidosis and primary hyperoxaluria require their specialist pathways.
- The source has differing antithrombotic bridging and restart instructions between narrative and table; no fixed hold, bridging or restart schedule is reproduced. Coordinate the individual plan with the prescribing specialist.
- The updated medical-expulsive-therapy section specifies distal stones 5–10 mm, while another section uses >5 mm; benefit is greatest in larger distal stones suitable for observation. Alkalinisation targets and cystine-treatment thresholds also vary by source section: use a supervised stone-specific protocol, not one universal pH or dose rule.
- The adult fluid and dietary advice must be individualised when other diseases constrain intake. Do not apply adult protein restriction or fluid-volume targets to children. Image-only metabolic and follow-up algorithms are not reproduced; this summary does not establish all drug doses or monitoring requirements.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Urolithiasis
Selected recommendation material consulted
Publication details
- Issuing organisation
- EAU
- Resource type
- Clinical guideline · House clinical summary
- Source setting
- Europe
Earlier House summaries: urolithiasis eau
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.